These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16044447)

  • 21. Successful use of a polymerized hemoglobin blood substitute in a critically anemic Jehovah's Witness.
    Allison G; Feeney C
    South Med J; 2004 Dec; 97(12):1257-8. PubMed ID: 15646766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report.
    Kącka K; Kącki W; Merak J; Błęka A
    Ortop Traumatol Rehabil; 2010; 12(5):448-58. PubMed ID: 21057153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.
    Ball AM; Winstead PS
    Pharmacotherapy; 2008 Nov; 28(11):1383-90. PubMed ID: 18956998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant factor VIIa for severe gastrointestinal hemorrhage associated with Crohn disease.
    Filik L
    South Med J; 2007 Jun; 100(6):559. PubMed ID: 17591308
    [No Abstract]   [Full Text] [Related]  

  • 26. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
    Sniecinski RM; Chen EP; Levy JH; Szlam F; Tanaka KA
    Anesth Analg; 2007 Apr; 104(4):763-5. PubMed ID: 17377078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy.
    Lim Y; Loo CC; Chia V; Fun W
    Int J Gynaecol Obstet; 2004 Nov; 87(2):178-9. PubMed ID: 15491576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergency subtotal colectomy in a Jehovah's Witness with massive lower gastrointestinal bleeding: challenges encountered and lessons learned.
    Raman SR; Parithivel VS; Cosgrove JM
    Am J Crit Care; 2011 Mar; 20(2):179, 176-8. PubMed ID: 21362723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tranexamic Acid for Treatment of Acute Gastrointestinal Bleeding in a Jehovah's Witness Patient on Apixaban and Dual Antiplatelet Therapy: A Case Report.
    Adv Emerg Nurs J; 2022 Jan-Mar 01; 44(1):E1. PubMed ID: 35089275
    [No Abstract]   [Full Text] [Related]  

  • 30. Recombinant Factor VIIa in blunt pelvic trauma.
    Hurst T; Blanckley S; Forrest M
    Anaesthesia; 2005 Dec; 60(12):1244-5; author reply 1245. PubMed ID: 16288629
    [No Abstract]   [Full Text] [Related]  

  • 31. [Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period].
    Tanchev S; Platikanov V; Markova S; Slavov N; Bogdanova A; Dimitrova D
    Akush Ginekol (Sofiia); 2004; 43(1):16-20. PubMed ID: 15168648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac surgery without blood products in a Jehovah's Witness child with factor VII deficiency.
    Pérez-Ferrer A; Gredilla E; de Vicente J; Laporta Y
    J Cardiothorac Vasc Anesth; 2012 Aug; 26(4):651-3. PubMed ID: 21924639
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparisons of cardiac surgery outcomes in Jehovah's versus Non-Jehovah's Witnesses.
    Stamou SC; White T; Barnett S; Boyce SW; Corso PJ; Lefrak EA
    Am J Cardiol; 2006 Nov; 98(9):1223-5. PubMed ID: 17056333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach.
    Hardy JF
    Can J Anaesth; 2002 Dec; 49(10):S4-6. PubMed ID: 12545999
    [No Abstract]   [Full Text] [Related]  

  • 35. Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate.
    Robblee JA; Wilkes PR; Dickie SJ; Rubens FD; Bormanis J
    Can J Anaesth; 2012 Mar; 59(3):299-303. PubMed ID: 22161243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contemporary approach to the care of Jehovah's witnesses.
    Hughes DB; Ullery BW; Barie PS
    J Trauma; 2008 Jul; 65(1):237-47. PubMed ID: 18580506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma.
    Zhou L; Mohsen A; Khan MA; Guthrie T
    J Chemother; 2014 Jun; 26(3):184-6. PubMed ID: 24621157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extreme anemia in an injured Jehovah's Witness: a test of our understanding of the physiology of severe anemia and the threshold for blood transfusion.
    Vaziri K; Roland JC; Robinson LL; Reines HD; Fakhry SM
    J Trauma; 2009 Jul; 67(1):E11-3. PubMed ID: 19590298
    [No Abstract]   [Full Text] [Related]  

  • 39. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency?
    Brown SA
    Haemophilia; 2005 Jul; 11(4):430-1. PubMed ID: 16011604
    [No Abstract]   [Full Text] [Related]  

  • 40. Analysis and results of the recombinant factor VIIa extended-use registry.
    Laffan M; O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy D; Smith OP
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S35-8. PubMed ID: 14567534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.